Jci_page_head_homepage_01 Jci_page_head_homepage_02
Vanda A. Lennon, Leonid G. Ermilov, Joseph H. Szurszewski, Steven Vernino
Published in Volume 111, Issue 6
J Clin Invest. 2003; 111(6):907–913 doi:10.1172/JCI17429
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1

Clinical outcome of immunization parallels ganglionic nAChR antibody response. (a) Serial levels of antibody in serum of 16 responder rabbits expressed for each individual as a percentage of the maximal attained level (mean 9.19 ± 1.84 nmol of [125I]epibatidine-complexed ganglionic nAChR bound per liter) and shown as means ± SEM of all normalized values. Two rabbits of 18 challenged with α3-GST protein remained seronegative. (b) Average daily food intake (± SEM) in rabbits producing ganglionic nAChR antibody and controls. Filled diamonds represent five responder rabbits immunized with α3-GST fusion protein, and open circles represent six rabbits immunized with a control GST protein. (c) Serial weight changes in α3-GST responder and nonresponder rabbits. Filled diamonds represent 16 rabbits producing ganglionic nAChR antibody, open circles represent 12 control rabbits (6 immunized with control GST fusion protein and 6 with adjuvant only), and open diamonds represent 2 individual rabbits that remained seronegative after α3-GST inoculation.